Resilience collaborates with the Mayo Clinic to manufacture rare and complex disease drugs
After netting its Series D round of funding in June, Resilience is not sitting around and resting on its laurels.
The Bob Nelsen-backed contract manufacturer on Monday announced a new strategic collaboration with the Mayo Clinic. The relationship is centered around manufacturing biotherapeutics for rare and complex conditions, with the focus on biologics including those based in cells, blood, enzymes, tissues, genes or genetically engineered cells.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.